Market Research Industry Reports

Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The companys lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercepts other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises US$30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Equity Offering 13
Intercept Pharma Prices Private Placement of Shares for USD100 Million 13
Intercept Pharma Prices Public Offering of Shares for USD150 Million 15
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters Exercise Of Over-Allotment Option For US$86 Million 25
Debt Offering 27
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Acquisition 29
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc - Key Competitors 30
Intercept Pharmaceuticals Inc - Key Employees 31
Intercept Pharmaceuticals Inc - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Feb 14, 2018: Intercept Pharmaceuticals Reports Net Sales Of $129.2 Million For The Year Ended December 31, 2017 34
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 37
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 39
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 41
Corporate Communications 44
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables

List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharma Raises US$30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Prices Private Placement of Shares for USD100 Million 13
Intercept Pharma Prices Public Offering of Shares for USD150 Million 15
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters Exercise Of Over-Allotment Option For US$86 Million 25
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32

List Of Figures

List of Figures
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The companys

USD 250View Report

Intercept Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Intercept Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Intercept Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Alexza Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Alexza Pharmaceuticals Inc (Alexza), a wholly owned subsidiary of Ferrer Therapeutics Inc, focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :45
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube